Efficacy and safety of biological agents in treatment of ankylosing spondylitis
A new direction of XXI century in the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, is characterized by using of target therapy with biological agentsthat contribute significant reduction in immunological processes, clinical symptoms and improving the quality of life for patients with those diseases. The article presents results ofthemulticenter, double-blind, placebo-controlled GO-RAISE, dedicated to the study of the efficacy and safety of the anti-TNF-αdrug golimumab in the treatment of ankylosingspondylitis.